First Quarter Financial Report | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16393
post-template-default,single,single-post,postid-16393,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

First Quarter Financial Report

First Quarter Financial Report

Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include:
  • Record level for total operating revenue of MNOK 11.2 for the quarter
  • 100 % growth in sales revenue compared to 1Q17
  • 24 % growth in sales revenue compared to 4Q17
  • Strong sales for both Cystatin C and fCal
  • New Proof-of-Concept announced post end of quarter

Please find the report enclosed. The report will also be made available on www.gentian.com.

For further information, please contact:
Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
MeldingsID: 451378